查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1786335

全球COVID-19药物输送装置市场

COVID-19 Drug Delivery Devices
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 277 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

预计到 2030 年，全球 COVID-19 药物输送设备市场规模将达到 16 亿美元

全球COVID-19药物输送设备市场规模在2024年估计为16亿美元，预计到2030年将达到16亿美元，在2024-2030年的分析期内，复合年增长率为-0.1%。预填充式注射器是本报告分析的细分市场之一，预计其复合年增长率为0.0%，到分析期结束时规模将达到7.906亿美元。无针注射器细分市场在分析期间的复合年增长率估计为-0.3%。

美国市场规模估计为 4.458 亿美元，中国市场预计复合年增长率为 0.1%

美国新冠药物输送设备市场规模预计2024年达到4.458亿美元。预计到2030年，作为世界第二大经济体的中国市场规模将达到2.768亿美元，在2024-2030年的分析期内，复合年增长率为0.1%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为-0.2%和-0.1%。在欧洲，预计德国市场的复合年增长率约为-0.2%。

全球 COVID-19 药物输送设备市场 - 主要趋势与驱动因素摘要

疫情如何改变药物输送：了解医疗保健重点的转变

COVID-19 大流行重塑了全球医疗保健产业，加速了对先进药物输送设备的需求，以确保有效且安全地使用抗病毒治疗剂和疫苗。 COVID-19 疫苗的快速研发和交付需要扩大注射器和自动注射器的生产，导致药物输送设备市场空前成长。此外，住院 COVID-19 患者激增，需要改善吸入和雾化疗法来治疗呼吸道併发症。这场大流行也凸显了自我给药解决方案的重要性，促使人们转向预填充式注射器、自动注射器和穿戴式药物输送系统。远端医疗整合和家庭医疗保健解决方案进一步刺激了对能够进行远端监控和剂量追踪的智慧型药物传输设备的需求。此外，对全球疫情防范的日益重视促使政府和製药公司投资扩充性且高效的药物输送基础设施。

哪些药物输送设备需求最大？探索关键产品细分市场

COVID-19 药物输送设备市场由多个部分组成，包括注射器、吸入器、自动注射器、输液帮浦和经皮贴片。预填充式注射器是疫苗接种中最关键的组件之一，製造商正在扩大产量以满足全球需求。雾化器和干粉吸入器等吸入式药物输送系统在管理 COVID-19 相关呼吸道併发症发挥关键作用，尤其是在高风险患者中。随着患者寻求非接触式、自我给药的治疗方案，胰岛素帮浦和智慧注射器等穿戴式药物传输设备越来越受欢迎。此外，用于疫苗输送的微针贴片的出现为传统注射提供了一种新的替代方案，减少了对低温运输储存的需求并提高了偏远地区的可及性。对针刺伤和患者依从性的担忧也在加速到无针药物输送系统的转变。

创新如何彻底改变 COVID-19 药物传输：人工智慧、奈米技术和智慧设备的作用

这次大流行刺激了药物输送设备的技术创新，从而开发出更有效率、更患者友善的解决方案。具有即时症状追踪功能的主导吸入器提高了呼吸系统治疗的依从性，特别是对于长期 COVID-19併发症。奈米技术在药物传输中的应用提高了 COVID-19 治疗的生物生物有效性和靶向作用，最大限度地减少了副作用并优化了治疗效果。此外，具有远端连接功能的智慧型药物传输设备可实现远端患者监控，减少就诊次数并改善医疗服务。温度稳定的疫苗製剂的开发，结合无针输送系统，正在解决与大规模疫苗宣传活动相关的后勤挑战。此外，生物製药的进步促成了长效抗病毒製剂的开发，减少了给药频率并提高了治疗效果。

推动COVID-19药物输送设备市场成长的因素有哪些？关键市场影响因素说明

COVID-19 药物输送设备市场的成长受到多种因素的推动，包括全球疫苗接种率的提高、药物输送技术的进步以及自我给药治疗方案的扩展。对生物製药的投资不断增加，加速了下一代药物输送解决方案的开发，提高了患者的依从性和治疗效果。电子商务和数位医疗平台的扩张也推动了自我给药设备的采用。此外，政府旨在防范疫情的措施正在增加可扩展疫苗分发和紧急医疗供应链的资金投入。向个人化医疗和标靶药物输送方法的转变正在进一步加强市场成长。随着医疗产业在后疫情时代继续发展，创新、数位整合和全球医疗基础设施的加强预计将推动 COVID-19 药物输送设备市场的扩张。

部分

产品（预填充式注射器、无针注射器、吸入器、贴剂）、给药途径（肠外、鼻内、其他）、通路（医院药局、零售药局、网路药局）

受访公司范例

  • ApiJect Systems Corp.
  • AstraZeneca plc
  • Becton, Dickinson and Company（BD）
  • Bharat Biotech
  • CanSino Biologics Inc.
  • Cardinal Health
  • Croda International Plc
  • Gerresheimer AG
  • GlaxoSmithKline plc（GSK）
  • Hindustan Syringes & Medical Devices Ltd.
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Moderna, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi SA
  • SCHOTT AG
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Terumo Corporation

人工智慧集成

我们正在利用有效的专家内容和人工智慧工具来改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 西班牙
  • 俄罗斯
  • 其他欧洲国家
  • 亚太地区
  • 澳洲
  • 印度
  • 韩国
  • 其他亚太地区
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中东
  • 伊朗
  • 以色列
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 其他中东地区
  • 非洲

第四章 竞赛

简介目录
Product Code: MCP30276

Global COVID-19 Drug Delivery Devices Market to Reach US$1.6 Billion by 2030

The global market for COVID-19 Drug Delivery Devices estimated at US$1.6 Billion in the year 2024, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of -0.1% over the analysis period 2024-2030. Prefilled Syringe, one of the segments analyzed in the report, is expected to record a 0.0% CAGR and reach US$790.6 Million by the end of the analysis period. Growth in the Needle-free Injectors segment is estimated at -0.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$445.8 Million While China is Forecast to Grow at 0.1% CAGR

The COVID-19 Drug Delivery Devices market in the U.S. is estimated at US$445.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$276.8 Million by the year 2030 trailing a CAGR of 0.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of -0.2% and -0.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately -0.2% CAGR.

Global COVID-19 Drug Delivery Devices Market - Key Trends & Drivers Summarized

How Has the Pandemic Transformed Drug Delivery? Understanding the Shift in Healthcare Priorities

The COVID-19 pandemic has reshaped the global healthcare industry, accelerating the demand for advanced drug delivery devices to ensure efficient and safe administration of antiviral treatments and vaccines. The rapid development and distribution of COVID-19 vaccines necessitated the expansion of syringe and auto-injector manufacturing, leading to unprecedented growth in the drug delivery devices market. Additionally, the surge in hospitalized COVID-19 patients required improved inhalation and nebulization therapies for managing respiratory complications. The pandemic also underscored the importance of self-administered drug delivery solutions, prompting a shift toward prefilled syringes, autoinjectors, and wearable drug delivery systems. Telemedicine integration and at-home healthcare solutions have further increased demand for smart drug delivery devices that enable remote monitoring and dosage tracking. Additionally, the rising emphasis on global pandemic preparedness has prompted governments and pharmaceutical companies to invest in scalable and efficient drug delivery infrastructure.

Which Drug Delivery Devices Have Seen the Highest Demand? Exploring Key Product Segments

The COVID-19 drug delivery devices market comprises various segments, including syringes, inhalers, autoinjectors, infusion pumps, and transdermal patches. Prefilled syringes have been one of the most critical components in vaccine administration, with manufacturers ramping up production to meet global demand. Inhalation drug delivery systems, including nebulizers and dry powder inhalers, have played a crucial role in managing COVID-19-related respiratory complications, particularly among high-risk patients. Wearable drug delivery devices, such as insulin pumps and smart injectors, have gained traction as patients seek contactless and self-administered treatment solutions. Additionally, the emergence of microneedle patches for vaccine delivery has introduced a novel alternative to traditional injections, reducing the need for cold-chain storage and improving accessibility in remote regions. The shift toward needle-free drug delivery systems has also accelerated, driven by concerns over needle-stick injuries and patient compliance.

How Is Innovation Revolutionizing COVID-19 Drug Delivery? The Role of AI, Nanotechnology & Smart Devices

The pandemic has driven a wave of technological innovations in drug delivery devices, leading to the development of more efficient, patient-friendly solutions. AI-driven inhalers equipped with real-time symptom tracking have enhanced respiratory treatment adherence, particularly for long-term COVID-19 complications. The integration of nanotechnology in drug delivery has improved the bioavailability and targeted action of COVID-19 therapeutics, minimizing side effects and optimizing treatment outcomes. Additionally, smart drug delivery devices with remote connectivity features have facilitated remote patient monitoring, reducing hospital visits and improving healthcare accessibility. The development of temperature-stable vaccine formulations, combined with needle-free delivery systems, has addressed logistical challenges associated with mass immunization campaigns. Furthermore, advancements in biopharmaceuticals have led to the creation of long-acting antiviral formulations, reducing the frequency of drug administration and enhancing treatment efficacy.

What’s Driving the Growth of the COVID-19 Drug Delivery Devices Market? Key Market Influencers Explained

The growth in the COVID-19 drug delivery devices market is driven by several factors, including increased global immunization efforts, advancements in drug delivery technology, and the expansion of self-administered treatment options. The rising investment in biopharmaceuticals has accelerated the development of next-generation drug delivery solutions, improving patient compliance and therapeutic outcomes. The expansion of e-commerce and digital healthcare platforms has also facilitated the widespread availability of self-administration drug delivery devices. Additionally, government initiatives aimed at pandemic preparedness have led to increased funding for scalable vaccine distribution and emergency medical supply chains. The shift toward personalized medicine and targeted drug delivery approaches has further strengthened market growth. As the healthcare industry continues to evolve post-pandemic, the COVID-19 drug delivery devices market is expected to expand, driven by innovation, digital integration, and enhanced global healthcare infrastructure.

SCOPE OF STUDY:

The report analyzes the COVID-19 Drug Delivery Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Prefilled Syringe, Needle-free Injectors, Inhalers, Patches); Route of Administration (Parenteral Administration, Nasal Administration, Other Administrations); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 43 Featured) -

  • ApiJect Systems Corp.
  • AstraZeneca plc
  • Becton, Dickinson and Company (BD)
  • Bharat Biotech
  • CanSino Biologics Inc.
  • Cardinal Health
  • Croda International Plc
  • Gerresheimer AG
  • GlaxoSmithKline plc (GSK)
  • Hindustan Syringes & Medical Devices Ltd.
  • Inovio Pharmaceuticals
  • Johnson & Johnson
  • Moderna, Inc.
  • Novartis International AG
  • Pfizer Inc.
  • Sanofi S.A.
  • SCHOTT AG
  • Serum Institute of India Pvt. Ltd.
  • Sinovac Biotech Ltd.
  • Terumo Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • COVID-19 Drug Delivery Devices - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Global Vaccine Distribution Drives Demand for Efficient COVID-19 Drug Delivery Devices
    • Growing Focus on Vaccine Equity and Accessibility Expands Addressable Market for Affordable Drug Delivery Solutions
    • Innovation in Needle-Free and Non-Invasive Drug Delivery Technologies Accelerates Adoption for COVID-19 Vaccines
    • Increasing Government Support and Funding for Vaccine Rollout Programs Propels Growth in Drug Delivery Device Development
    • Technological Advancements in Microneedle Patches Strengthen the Business Case for Non-Traditional Vaccine Delivery Methods
    • The Need for Mass Immunization Drives Adoption of Scalable, High-Efficiency Drug Delivery Devices
    • Rising Preference for Self-Administration and At-Home Vaccine Delivery Solutions Expands Market Opportunities
    • Expansion of Cold Chain Logistics and Temperature-Sensitive Packaging Solutions Supports Growth in Drug Delivery Devices
    • Heightened Focus on Global Pandemic Preparedness Stimulates Innovation in Rapid Response Drug Delivery Systems
    • Regulatory Approvals for Emergency Use Authorizations (EUAs) Accelerate the Development and Distribution of COVID-19 Drug Delivery Devices
    • Consumer Trust in New Vaccine Technologies Drives Demand for Safe, Reliable Drug Delivery Mechanisms
    • Global Push for Digital Health Solutions Expands Adoption of Connected Drug Delivery Devices with IoT Integration
    • Increasing Public-Private Partnerships for Vaccine Research and Development Expands Opportunities for Drug Delivery Device Manufacturers
    • Rise in Immunocompromised Populations and Increased Health Risks Post-Pandemic Sustains Demand for Effective Drug Delivery Systems
    • Growth in Collaborative Research Between Pharma Companies and Tech Firms Drives Innovation in Delivery Device Designs
    • Push for Streamlined Healthcare Supply Chains Strengthens Market Demand for Cost-Effective Drug Delivery Solutions
    • Emergence of New Variants of COVID-19 Drives Demand for Advanced, Flexible Drug Delivery Devices to Address Evolving Therapeutic Needs
    • Increased Investment in AI and Machine Learning for Personalized Vaccine Dosing Expands Market Potential for Smart Drug Delivery Systems
    • Rising Focus on Patient Comfort and Experience Spurs Growth in Painless and Low-Discomfort Delivery Devices
    • Evolving Regulatory Landscape and Compliance Challenges in Vaccine Delivery Highlight the Need for Robust, Adaptable Drug Delivery Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World COVID-19 Drug Delivery Devices Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for COVID-19 Drug Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Prefilled Syringe by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Prefilled Syringe by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Needle-free Injectors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Needle-free Injectors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inhalers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Inhalers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Patches by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Patches by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Parenteral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Parenteral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Nasal Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Nasal Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Other Administrations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Other Administrations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 24: USA Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • CANADA
    • TABLE 30: Canada Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • JAPAN
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 36: Japan Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • CHINA
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 42: China Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • EUROPE
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 48: Europe Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for COVID-19 Drug Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • FRANCE
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • GERMANY
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • UNITED KINGDOM
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 82: Spain Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Spain 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 84: Spain Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Spain 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 88: Russia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Russia 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 90: Russia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Russia 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 94: Rest of Europe Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of Europe 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 96: Rest of Europe Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of Europe 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • ASIA-PACIFIC
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific 6-Year Perspective for COVID-19 Drug Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 100: Asia-Pacific Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Asia-Pacific 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 102: Asia-Pacific Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Asia-Pacific 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • AUSTRALIA
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 106: Australia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Australia 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 108: Australia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Australia 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • INDIA
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 112: India Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: India 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 114: India Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: India 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 118: South Korea Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: South Korea 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 120: South Korea Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: South Korea 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 124: Rest of Asia-Pacific Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of Asia-Pacific 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 126: Rest of Asia-Pacific Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • LATIN AMERICA
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 130: Latin America Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 131: Latin America 6-Year Perspective for COVID-19 Drug Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 132: Latin America Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Latin America 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 136: Latin America Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Latin America 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 138: Argentina Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 139: Argentina 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 142: Argentina Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 143: Argentina 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • BRAZIL
    • TABLE 144: Brazil Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 145: Brazil 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 148: Brazil Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 149: Brazil 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • MEXICO
    • TABLE 150: Mexico Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 151: Mexico 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 154: Mexico Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 155: Mexico 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 156: Rest of Latin America Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 157: Rest of Latin America 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 160: Rest of Latin America Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 161: Rest of Latin America 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • MIDDLE EAST
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 162: Middle East Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 163: Middle East 6-Year Perspective for COVID-19 Drug Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 166: Middle East Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 167: Middle East 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 168: Middle East Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 169: Middle East 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 172: Iran Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 173: Iran 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 174: Iran Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 175: Iran 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 178: Israel Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 179: Israel 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 180: Israel Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 181: Israel 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 184: Saudi Arabia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 185: Saudi Arabia 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 186: Saudi Arabia Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 187: Saudi Arabia 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 190: UAE Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 191: UAE 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 192: UAE Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 193: UAE 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 196: Rest of Middle East Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 197: Rest of Middle East 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 198: Rest of Middle East Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 199: Rest of Middle East 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030
  • AFRICA
    • COVID-19 Drug Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Product - Prefilled Syringe, Needle-free Injectors, Inhalers and Patches - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa 6-Year Perspective for COVID-19 Drug Delivery Devices by Product - Percentage Breakdown of Value Sales for Prefilled Syringe, Needle-free Injectors, Inhalers and Patches for the Years 2025 & 2030
    • TABLE 202: Africa Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Distribution Channel - Online Pharmacies, Hospital Pharmacies and Retail Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 203: Africa 6-Year Perspective for COVID-19 Drug Delivery Devices by Distribution Channel - Percentage Breakdown of Value Sales for Online Pharmacies, Hospital Pharmacies and Retail Pharmacies for the Years 2025 & 2030
    • TABLE 204: Africa Recent Past, Current & Future Analysis for COVID-19 Drug Delivery Devices by Route Of Administration - Parenteral Administration, Nasal Administration and Other Administrations - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 205: Africa 6-Year Perspective for COVID-19 Drug Delivery Devices by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral Administration, Nasal Administration and Other Administrations for the Years 2025 & 2030

IV. COMPETITION